

1/29




FIG. 1

2/29




FIG. 2

3/29

310	320	330	340
Cancer type	Gain	Loss	Reference
Thyroid cancer	7p, 8q, and 9q	22	Hemmer et al. Am J Pathol, 1999;154:1539-47.
Gastric cancer	2q37, 3p21, 5q34-35, 7q34-36, 11q13, 11q23-25, 12q24, 15q23-25, 17q21-25, and 20q12-13	4q, 13q, 5q, 6q, and 18p	Noguchi et al. Am J Clin Pathol 2001; 115:828-34
Prostate cancer	1q32, 3q26, 4q26, 7q21, 8q22, 9q33, 17q25, and Xq21	2q22, 4q27-4q28, 5q15, 6q15, 8p21, 10q23, 12p13, 13q21, 15q23, 16q22, and 18q21-22	Sun et al. Prostate 2007;67:692-700.
Small cell lung cancer	3q26-29, 5p12-13, and 8q23-24	3p13-14, 4q32-35, 5q32-35, 8p21-22, 10q25, 13q13-14, and 17p12-13	Balsara et al. Oncogene 2002;21:6877-83.
Non small cell lung cancer	1q31, 3q25-27, 5p13-14, and 8q23-24	31p21, 8p22, 9p21-22, 13q22, and 17p12-13	Balsara et al. Oncogene 2002;21:6877-83.
Nasopharyngeal carcinoma	1p34, 3q26, 6q25, and 3q26	3p, 9p, 9q, 11q, 13q, and 14q	Lo et al. Semin Cancer Biol 2002;12:451-62
Bladder cancer	1q, 5p, 6p, 8q, 11q, 17q, and 20q	3p, 4q, 4q, 6q, 8p, 9p, and 18q	El-Rifai et al. Am J Pathol 2000;156:871-8
Colorectal cancer	13q and 20q	4q and 18q	De Angelis et al. Int J Colorectal Dis 2001;16:38-45.
Head and neck cancer	3q26 and 11q13	3p, 9p, and 17p	Smeets et al. Oncogene 2006;25:2558-64
Melanoma	1q, 2, 6p, 7, 8, 17, and 20	6q, 8p, 9, and 10	Bastian et al. Cancer Res 1998;58:2170-5.
Lymphoma	1q, 3, 6p, 7, 11, 12, 18, and X	1p, 8p, and X	Monni et al. Blood 1996;87:5269-78

FIG. 3

 300




FIG. 4

5/29




FIG. 5




FIG. 6

7/29




FIG. 7

8/29




FIG. 8

9/29




FIG. 9

10/29

1000




FIG. 10

11/29





FIG. 11






FIG. 13




FIG. 14

15/29

1500

Fractional concentration of cancer-derived DNA 1510	Estimated no. of molecules required per segment 1520	Size of each segment (kb) 1530	Total no. of molecules to be analyzed for the whole genome (million) 1540
50%	950	100	28.5
		1,000	2.85
		5,000	0.570
		10,000	0.285
25%	3,800	100	114
		1,000	11.4
		5,000	2.28
		10,000	1.14
12.5%	15,000	100	450
		1,000	45
		5,000	9
		10,000	4.5
6.3%	60,000	100	1,800
		1,000	180
		5,000	36
		10,000	18
3.2%	240,000	100	7,200
		1,000	720
		5,000	144
		10,000	72

FIG. 15




FIG. 16

17/29

1700




FIG. 17

18/29




FIG. 18A





FIG. 18B

19/29

Chromosomal aberrations in HCC

FIG. 19



20/29




FIG. 20A




FIG. 20B

21/29




FIG. 21




FIG. 22

23/29




FIG. 23

24/29




FIG. 24

25/29




FIG. 25




FIG. 26

27/29




FIG. 27

28/29




FIG. 28

